ClinicalTrials.gg
Sign In
Not yet recruitingNCT07766356P-CLACUpdated Aug 14, 2026

Study of Cognitive-Linguistic Profiles: The Role of Executive Control in Aphasia

An interventional study of Neuropsychological tests and Speech-language assessments in Stroke, sponsored by University Hospital, Toulouse. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

In France, stroke affects 150,000 people annually and is the leading cause of acquired disability in adults; 10-12% of patients exhibit mild post-stroke aphasia, a condition defined by language difficulties.

Few studies describe mild post-stroke aphasia, and none characterize the impairment of linguistic executive control in this population; consequently, its prevalence remains unknown. To date, the role of linguistic executive control in mild aphasia remains an open question.

The aim of this project is to investigate linguistic executive control impairment in stroke survivors with mild aphasia, provide an initial estimate of its prevalence, and demonstrate its interactions with other linguistic and communicative aspects, as well as with executive and attentional functions.

02

Conditions studied

  • Stroke

Browse trials for

Keywords

  • stroke
  • aphasia
  • AVC
03

In context

Stroke

8,255 studies on the registry are indexed under Stroke; 2,056 are open to participants now.

This study's planned enrollment of 30 is below the median of 49 across 6,024 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

University Hospital, Toulouse is the lead sponsor of 807 studies on the registry; 209 are open to participants now.

Browse University Hospital, Toulouse studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient who has experienced a first ischemic stroke resulting in clinical symptoms within the last 3 months and is receiving care in the Physical Medicine and Rehabilitation department.
  • Score ≤ 31 on the conversational speech observation scale of the MEC test (Montreal Protocol for the Evaluation of Communication).
  • Patients with a BDAE score ≥ 3 (Boston Diagnostic Aphasia Examination - French version, Mazaux J.-M. [1990]); this score is the gold standard in aphasiology.
  • Native French-speaking patient capable of understanding oral or written instructions.

Exclusion criteria

Exclusion Criteria:

  • Patients exhibiting behavior or a clinical condition incompatible with test administration, as assessed by the clinician.
  • Known major visual, auditory, or motor impairments incompatible with test performance.
  • Known neurodegenerative and/or neurodevelopmental disorders.
  • Known social cognition disorders (e.g., ASD).
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Patients whose neuropsychological and speech-language pathology tests will be randomized

    Diagnostic Test: Neuropsychological tests · Diagnostic Test: Speech-language assessments

Interventions

  • Diagnostic testNeuropsychological tests

    Patients undergo neuropsychological tests, the order of which will be randomized.

  • Diagnostic testSpeech-language assessments

    Patients will undergo speech-language assessments, with the order of the tests randomized.

06

What researchers measure

Primary outcomes

  1. measure the proportion of patients with mild post-stroke aphasia exhibiting deficits in linguistic executive control within three months of a first stroke

    CATEX score result (deficit score if below the mean value minus 1.65 times the standard deviation)

    Time frame: 7 days after the inclusion

Secondary outcomes

  1. Study of the correlation between executive control of language (CATEX score) and the score of the test evaluating access to the lexical stock

    Time frame: 7 days after the inclusion

  2. Study of the correlation between linguistic executive control (CATEX score) and the score of the test evaluating access to the semantic system

    Time frame: 7 days after the inclusion

  3. Study of the correlation between linguistic executive control (CATEX score) and the score of the test evaluating non-verbal executive control

    Time frame: 7 days after the inclusion

  4. Study of the correlation between linguistic executive control (CATEX score) and the score of the test evaluating gnosies

    Time frame: 7 days after the inclusion

  5. Identification of patients' cognitive-linguistic impairment profiles based on cognitive test scores

    Time frame: 7 days after the inclusion

  6. Identification of patients' cognitive-linguistic impairment profiles based on stroke location using factor analysis

    Time frame: 7 days after the inclusion

07

Study locations

1 site
  • Service de Médecine Physique et de Réadaptation Hôpital Raymonde Fournet Purpan
    Toulouse, 31300, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2028, 24 months later.

Of 3,108 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 24 months is close to that.

Counting every sponsor, half of 3,252 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Aug 14, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 8, 2028
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07766356
Lead sponsor
University Hospital, Toulouse
Responsible party
Sponsor
First posted
Aug 14, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 8, 2028 (estimated)
Last update
Aug 14, 2026

Study contacts

Elodie GUILLOUET
Contact
guillouet.E@chu-toulouse.fr
0561779072 ext. +33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Stroke →

Other studies from this sponsor

University Hospital, Toulouse →

Start the discussion